See more : The Grob Tea Company Limited (GROBTEA.NS) Income Statement Analysis – Financial Results
Complete financial analysis of Hansa Biopharma AB (publ) (HNSBF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Hansa Biopharma AB (publ), a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- RBC Bearings Incorporated (RBCP) Income Statement Analysis – Financial Results
- E. Bon Holdings Limited (0599.HK) Income Statement Analysis – Financial Results
- Boustead Singapore Limited (F9D.SI) Income Statement Analysis – Financial Results
- CJ Logistics Corporation (000120.KS) Income Statement Analysis – Financial Results
- Softline Holding PLC (SFTL.ME) Income Statement Analysis – Financial Results
Hansa Biopharma AB (publ) (HNSBF)
About Hansa Biopharma AB (publ)
Hansa Biopharma AB (publ), a biopharmaceutical company, develops immunomodulatory treatments for enabling transplants and rare immunoglobulin G (IgG)-mediated autoimmune conditions, gene therapy, and cancer using its proprietary enzyme technology platform. The company's lead drug candidate is Imlifidase, an antibody cleaving enzyme therapy that is in phase 3 clinical trial for use in sensitized kidney transplantations patients, as well as for anti-GBM antibody disease; and phase 2 clinical trial for antibody-mediated kidney transplant rejection and Guillain Barré syndrome. It is also developing Novel immunoglobulin cleaving enzymes for Repeat dosing (NiceR) for the treatment of autoimmune diseases, transplantation, and oncology; and Enzyme based antibody Enhancement (EnzE), which is cancer immunotherapy. The company has a preclinical research collaboration agreement with argenx BV to evaluate the therapeutic potential of combining the two companies' IgG-modulating technologies. Hansa Biopharma AB (publ) was incorporated in 2007 and is headquartered in Lund, Sweden.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 134.09M | 154.53M | 33.88M | 6.10M | 3.36M | 3.36M | 3.44M | 2.58M | 5.43M | 4.72M | 1.73M | 2.62M | 1.28M | 4.45M | 2.98M | 103.68K |
| Cost of Revenue | 63.14M | 38.48M | 15.43M | 997.00K | 866.00K | 916.00K | 221.00K | 217.00K | 658.00K | 245.00K | 317.96K | -2.49M | 1.71M | 0.00 | 0.00 | 0.00 |
| Gross Profit | 70.95M | 116.05M | 18.45M | 5.10M | 2.50M | 2.44M | 3.22M | 2.36M | 4.78M | 4.47M | 1.41M | 5.11M | -432.44K | 4.45M | 2.98M | 103.68K |
| Gross Profit Ratio | 52.91% | 75.10% | 54.47% | 83.65% | 74.26% | 72.72% | 93.58% | 91.59% | 87.89% | 94.80% | 81.59% | 194.96% | -33.73% | 100.00% | 100.00% | 100.00% |
| Research & Development | 411.33M | 346.24M | 230.76M | 227.19M | 192.95M | 154.56M | 137.06M | 82.85M | 44.26M | 21.74M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 450.49M | 337.86M | 327.27M | 202.99M | 167.31M | 90.39M | 43.72M | 29.70M | 28.24M | 17.42M | 11.26M | 14.14M | 21.16M | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 450.49M | 337.86M | 327.27M | 202.99M | 167.31M | 90.39M | 43.72M | 29.70M | 28.24M | 17.42M | 11.26M | 14.14M | 21.16M | 0.00 | 0.00 | 0.00 |
| Other Expenses | -2.38M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 859.45M | 692.17M | 558.03M | 430.18M | 360.09M | 244.22M | 179.34M | 113.50M | 70.98M | 29.18M | 19.05M | 21.91M | 27.46M | 24.44M | 18.72M | 16.01M |
| Cost & Expenses | 922.59M | 730.65M | 573.46M | 431.18M | 360.96M | 245.14M | 179.56M | 113.71M | 71.64M | 29.43M | 19.37M | 19.43M | 29.18M | 24.44M | 18.72M | 16.01M |
| Interest Income | 27.99M | 8.83M | 67.00K | 388.00K | 118.00K | 52.00K | 97.00K | 23.00K | 0.00 | 42.00K | 93.22K | 346.44K | 47.78K | 0.00 | 0.00 | 0.00 |
| Interest Expense | 105.52M | 43.67M | 694.00K | 257.00K | 466.00K | 706.00K | 695.00K | 103.00K | 65.00K | 123.00K | 15.76K | 4.74K | 155.41K | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 19.79M | 12.05M | 8.61M | 7.55M | 6.91M | 1.84M | 3.78M | 3.45M | 989.00K | 1.35M | 96.65K | 126.79K | -52.36M | 0.00 | 381.77K | 415.40K |
| EBITDA | -705.50M | -554.26M | -538.83M | -414.75M | -351.66M | -245.47M | -172.23M | -107.60M | -65.21M | -24.48M | -17.45M | -16.27M | -24.29M | -19.99M | -15.36M | -15.47M |
| EBITDA Ratio | -526.12% | -355.47% | -1,588.95% | -6,801.44% | -10,466.94% | -7,284.69% | -5,004.68% | -4,174.49% | -1,200.07% | -494.44% | -1,010.39% | -623.73% | -2,175.42% | -449.46% | -514.75% | -14,925.86% |
| Operating Income | -788.50M | -588.59M | -546.98M | -422.81M | -359.67M | -246.50M | -176.08M | -111.14M | -66.20M | -24.71M | -17.64M | -16.81M | 24.46M | -19.99M | -15.74M | -15.91M |
| Operating Income Ratio | -588.02% | -380.90% | -1,614.55% | -6,933.54% | -10,691.68% | -7,340.62% | -5,115.72% | -4,309.23% | -1,218.27% | -523.94% | -1,021.38% | -641.80% | 1,907.97% | -449.46% | -527.54% | -15,341.72% |
| Total Other Income/Expenses | -42.32M | -33.86M | -1.15M | 1.91M | -2.00M | -6.24M | -616.00K | -17.00K | -65.00K | -4.33M | 67.00K | 331.97K | -107.63K | -150.48K | -71.60K | 16.52M |
| Income Before Tax | -830.81M | -609.98M | -548.13M | -420.89M | -359.59M | -248.01M | -176.70M | -111.15M | -66.27M | -29.04M | -17.56M | -16.47M | -24.57M | -20.14M | -15.81M | 616.70K |
| Income Before Tax Ratio | -619.57% | -394.74% | -1,617.95% | -6,902.15% | -10,689.42% | -7,385.77% | -5,133.61% | -4,309.89% | -1,219.47% | -615.82% | -1,016.90% | -628.75% | -1,916.36% | -452.84% | -529.94% | 594.83% |
| Income Tax Expense | 908.00K | 1.16M | 152.00K | -40.00K | 417.00K | -40.00K | -39.00K | -23.00K | 0.00 | 42.00K | 93.22K | 346.44K | 65.00 | -1.30M | 0.00 | 3.17M |
| Net Income | -831.72M | -611.13M | -548.28M | -420.85M | -360.01M | -247.97M | -176.66M | -111.13M | -66.27M | -29.04M | -17.56M | -16.47M | -24.57M | -18.84M | -15.81M | -2.56M |
| Net Income Ratio | -620.25% | -395.49% | -1,618.40% | -6,901.49% | -10,701.81% | -7,384.57% | -5,132.48% | -4,309.00% | -1,219.47% | -615.82% | -1,016.90% | -628.75% | -1,916.37% | -423.62% | -529.94% | -2,467.50% |
| EPS | -15.83 | -13.60 | -12.33 | -9.98 | -9.00 | -6.47 | -4.97 | -3.37 | -2.12 | -1.09 | -0.72 | -0.71 | -2.11 | -2.27 | -3.12 | -0.51 |
| EPS Diluted | -15.83 | -13.60 | -12.33 | -9.98 | -9.00 | -6.47 | -4.96 | -3.37 | -2.12 | -1.09 | -0.72 | -0.71 | -2.11 | -2.27 | -3.12 | -0.51 |
| Weighted Avg Shares Out | 52.54M | 44.92M | 44.47M | 42.18M | 40.02M | 38.33M | 35.52M | 33.01M | 31.21M | 26.54M | 24.54M | 23.24M | 11.64M | 8.31M | 5.06M | 5.00M |
| Weighted Avg Shares Out (Dil) | 52.54M | 44.92M | 44.47M | 42.18M | 40.02M | 38.33M | 35.61M | 33.01M | 31.21M | 26.54M | 24.54M | 23.24M | 11.64M | 8.31M | 5.06M | 5.00M |
Hansa Biopharma interim report January-March 2024
Strong sales performance and solid momentum with the Phase 3 trial in anti-GBM disease Cash runway extended into 2026 Evan Ballantyne joins Hansa Biopharma as Chief Financial Officer LUND, Sweden , April 18, 2024 /PRNewswire/ -- Hansa Biopharma, the pioneer...
Hansa Biopharma Expects Strong First Quarter 2024 Sales Performance
Company expects revenue of SEK 54m including product sales of SEK 48m - an increase of 10% versus the prior quarter and a 234% increase versus Q1 2023 Q1 2024 is the first time Hansa has delivered two consecutive quarters...
Evan Ballantyne to join Hansa Biopharma as Chief Financial Officer
LUND, Sweden , Feb. 22, 2024 /PRNewswire/ -- Hansa Biopharma, "Hansa" (Nasdaq Stockholm: HNSA), today announced the appointment of Evan Ballantyne as Chief Financial Officer (CFO), effective 1 March 2024. He succeeds Donato Spota, who, as previously announced, will leave the...
Hansa Biopharma AB (publ) (HNSBF) Q4 2023 Earnings Call Transcript
Hansa Biopharma AB (publ) (HNSBF) Q4 2023 Earnings Call Transcript
Hansa Biopharma Year-end report January-December 2023
Strong revenue generation in Q4 2023 including SEK 43m in Idefirix® product sales supported by growth in new markets such as U.K., Germany, and Spain Encouraging results from first-in-human trial of HNSA-5487 ...
Hansa Biopharma provides update on business and key financials ahead of the JP Morgan Healthcare Conference
Strong revenue generation in Q4 2023, including SEK 43m in Idefirix® product sales supported by growth in new markets such as U.K., Germany, and Spain Encouraging first results from first-in-human trial of HNSA-5487, Hansa's lead candidate from the NiceR program for repeat...
Hansa Biopharma Nomination Committee formed
LUND, Sweden , Dec. 13, 2023 /PRNewswire/ -- Hansa Biopharma today announced that the Nomination Committee has been formed in accordance with the principles adopted by the Annual General Meeting (AGM) on June 29, 2023 and has the following composition:...
Hansa Biopharma Interim Report January-September 2023
• Encouraging high-level results for first-in-human trial of HNSA-5487 • Well attended Hansa-sponsored symposium at ESOT focusing on first patient experiences • Dr. Hitto Kaufmann appointed new CSO LUND, Sweden , Oct. 26, 2023 /PRNewswire/ -- Hansa Biopharma, the pioneer...
Hansa Biopharma announces encouraging high-level results for first-in-human trial of HNSA-5487
HNSA-5487 is a next-generation IgG-cleaving enzyme and the lead candidate in the NiceR development program LUND, Sweden , Oct. 9, 2023 /PRNewswire/ -- Hansa Biopharma, "Hansa" (Nasdaq Stockholm: HNSA), a pioneer in enzyme technology for rare immunological conditions, today announced high-level...
Hansa Biopharma AB (publ) (HNSBF) Q2 2023 Earnings Call Transcript
Hansa Biopharma AB (publ) (OTCPK:HNSBF) Q2 2023 Earnings Call Transcript July 20, 2023 8:00 AM ET Company Participants Soren Tulstrup - President and CEO Matthew Shaulis - CCO Donato Spota - SVP and CFO Conference Call Participants Gonzalo Attali -...
Source: https://incomestatements.info
Category: Stock Reports